Quarterly update stated:
" 25 clinical delivery sites have signed Oventus as the EXCLUSIVE supplier of dental sleep services with minimum quantities of 20 devices per site per month"
Seems strange a sleep service provider would make Oventus the exclusive provider if they did not have confidence in the product
There is a lag of up to 90 days to get up to the minimum quota .
My calculations show over the last 5 months they are averaging at least 1 new site per week.
My guess is they could be cashflow positive after 90 sites are signed up assuming average 30 sales per month , at $A300 gross profit per unit.
They do seem to have bloated admin and staff costs for such a small company at $2M a quarter hopefully the deal with Lyon dental as a provider of reimbursement services will reduce admin costs per unit sold .
Hopefully Oventus will also learn from Lyon how to stream line their own in house admin and staff costs
Their spend on advertising and sales seems about right at 527K a quarter given they are having to install scanning equipment in labs and this is not shown to be amortised so guessing costed into the quarterlies which is a really a once off cost, would have been good if Oventus could have qualified how this is costed out ?
The R&D costs have always been low for the company and is especially apparent for the level of inventiveness the company has crystallised into product since inception , which is a dichotomy to the admin and staff costs.
My guess we will have receipts at around $120K for the Dec quarter so around a 25% gain on the Sept quarter, there should be exponential sales growth going forward given the product's efficacy compared to substitutes
OVN Price at posting:
48.5¢ Sentiment: Hold Disclosure: Held